Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Medicine of older adults indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Polypharmacy and structured medication review

Medicine of older adults · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Polypharmacy with immediate medicine harm

New coma, respiratory depression, severe hypoglycaemia, bleeding, arrhythmia, serotonin toxicity, anticholinergic delirium, acute kidney injury or profound hypotension may be caused or amplified by medicines and interactions.

Action: Use ABCDE and capillary glucose, stop further suspected exposure, identify every medicine and last dose, obtain targeted ECG and laboratory tests, and give time-critical antidote or supportive treatment with poisons, pharmacy and specialist advice as appropriate.

Overview

Recognise when multiple medicines create disproportionate burden, reconcile what is actually taken, and complete a person-centred structured review that protects essential treatment while improving safety, function and adherence.

Start with what matters now: living situation, prognosis, frailty, cognition, falls, continence, pain, sleep, mobility and the person's treatment priorities. Ask which medicines help, which are burdensome and what outcome they most want to avoid. A prevention-focused regimen may remain right for a robust older adult yet be poorly aligned with severe frailty, recurrent falls or limited life expectancy.

Construct the best possible medicines history from at least two reliable sources where uncertainty matters: the person or carer, GP repeat list, community pharmacy, hospital record, monitored pack and specialist correspondence. Include inhalers, eye drops, patches, injections, creams, supplements, alcohol and purchased remedies. Record allergies and adverse reactions separately from preferences or ineffective treatments.

For each item establish the original and current indication, measurable benefit, dose, route, duration, adherence, monitoring and prescriber. Identify duplication by ingredient rather than brand. A medicine without a recorded indication is a signal to investigate, not automatic permission to stop; corticosteroids, antiepileptics, beta-blockers, benzodiazepines and several psychotropics can harm if withdrawn abruptly.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Medicine of older adultsOriginal SBA

Starting a structured review

An 84-year-old with falls and CKD has three different medicine lists after discharge and cannot explain which tablets are taken. What is the best first step?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Medicine of older adults topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG5 medicines optimisationReconciliation, structured review, shared decisions and communication.
  • NICE NG56 multimorbidityGoals, treatment burden, frailty and individualised plans.
  • NHS England structured medication reviewsStructured review principles and priority groups in primary care.
  • British Geriatrics Society CGA HubFunctional, cognitive, social and multidisciplinary assessment.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom

Link symptoms to exposure and chronology. Dizziness may reflect alpha blockade, nitrates, antihypertensives, diuretics or dehydration; confusion may reflect anticholinergic and sedative summation; constipation may reflect opioids, iron or antimuscarinics. Examine lying and standing blood pressure, hydration, cognition, gait and relevant systems. Check whether the symptom began after initiation, dose increase, formulation change or acute illness.

Review benefit in the context of time to benefit and competing risk. Disease-modifying and symptom-control treatments can remain valuable during frailty, while low-value duplication or prevention with little realistic benefit may not. Use shared decision making and explain uncertainty. Avoid substituting chronological age for clinical judgement or denying treatment simply because the list is long.

Assess pharmacokinetic safety. Weight, renal trajectory, liver disease, albumin, hydration and acute illness modify exposure. For direct oral anticoagulants and other specified medicines, use Cockcroft–Gault creatinine clearance with current weight rules when the product guidance requires it. Review interacting inhibitors, inducers and additive effects, and arrange drug concentrations only when clinically interpretable.

Assess practical administration. Observe inhaler or injection technique; ask who orders, collects, stores and prompts doses; check child-resistant packaging, dexterity, vision, hearing and swallowing. A blister pack cannot correct a wrong regimen, and it may reduce flexibility. Pharmacy, occupational therapy, speech and language therapy, district nursing and social care can address specific barriers.

Agree decisions in priority order: urgent toxicity and dangerous interaction, missing essential treatment, monitoring failure, symptom burden, adherence barriers and longer-term optimisation. Preserve one clear list. Explain what changes today, what remains under review and what symptoms require help. When several changes are needed, stage them so benefit, withdrawal and relapse remain attributable.

Document the person's involvement and capacity for the decision. If capacity is lacking, support communication, consult those close to the person and make a best-interests decision under the Mental Capacity Act, considering known wishes and the least restrictive workable plan. A relative does not automatically consent unless they hold relevant legal authority.

Follow through after transitions. Send indication, dose, stop reason, monitoring, pending results and restart criteria to every relevant setting. Reconcile again after discharge or care-home transfer. A review is complete only when agreed changes have been implemented, required monitoring occurs and the person knows whom to contact.

Key points

  • Polypharmacy describes medicine count, whereas problematic polypharmacy means the combined regimen no longer delivers acceptable benefit, safety or practical fit.
  • First-line review begins with reconciliation: prescribed, dispensed and actually taken medicines, including non-prescription products, doses, timing, indication and last use.
  • Prioritise people with frailty, multimorbidity, recent admission, falls, delirium, renal decline, high-risk medicines, adherence difficulty or major treatment change.
  • A structured medication review is a shared, holistic clinical review, not an automated deletion exercise or a check confined to interaction software.
  • For every medicine ask: current indication, evidence of benefit, time to benefit, ongoing need, safety, monitoring, formulation, adherence and the person's goal.
  • Review high-risk combinations explicitly: anticoagulants and antiplatelets, opioids and sedatives, anticholinergics, insulin or sulfonylureas, diuretics and renally cleared medicines.
  • Estimate renal function using the method required for the medicine; eGFR and Cockcroft–Gault creatinine clearance are not interchangeable for every drug.
  • Change one or a small number of medicines at a time where feasible, document the reason, and provide withdrawal, relapse and monitoring plans.
  • Use capacity support, accessible information, interpreter or advocate, monitored dosage systems and carer involvement only when these solve an identified barrier.
  • Communicate the final list, stopped medicines, pending tests and named owners across GP, pharmacy, care setting and specialist teams.

Aetiology

01

Accumulated disease-specific prescribing

Separate guideline treatments build over years while no clinician reassesses the combined burden, competing priorities or altered goals.

02

Transitions and fragmented records

Hospital discharge, specialist clinics, repeat systems and community supply can create duplication, omissions, unexplained substitutions and stale prescriptions.

03

Age and organ change

Frailty, lower body mass, reduced renal or hepatic clearance and altered receptor sensitivity make a previously tolerated regimen hazardous.

04

Prescribing cascades

An adverse effect is mislabelled as a new disease and treated with another medicine, concealing the original drug-related cause.

Pathophysiology

  1. 1
    Exposure accumulation

    Reduced clearance, active metabolites and repeated dosing increase concentration and duration, especially during dehydration or acute kidney injury.

  2. 2
    Pharmacodynamic summation

    Several sedating, anticholinergic, hypotensive, bleeding or glucose-lowering effects combine even when each medicine is individually appropriate.

  3. 3
    Treatment-burden failure

    Complex timing, swallowing difficulty, impaired dexterity and cognition exceed practical capacity, producing erratic adherence and unstable exposure.

  4. 4
    Goal competition

    Long-term prevention can conflict with immediate mobility, continence, cognition, comfort or survival priorities in multimorbidity and frailty.

Clinical features and red flags

Problematic polypharmacy

Falls, treatment burden, interactions or unclear benefit outweigh the combined regimen's current value.

Prescribing cascade

A new medicine treats an adverse effect of an existing medicine without recognising the original cause.

Transition discrepancy

The discharge list, repeat record, dispensing history and actual administration disagree materially.

Organ-function accumulationRed flag

New sedation, bleeding or toxicity follows renal, hepatic, weight or hydration decline.

Administration incapacity

Cognitive, sensory, swallowing or dexterity problems make unsupervised dosing unreliable or unsafe.

Essential omissionRed flag

An indicated medicine such as insulin, steroid replacement or antiseizure therapy is absent or unintentionally stopped.

Red flags requiring action

  • Reduced consciousness, slow breathing or pinpoint pupils in an opioid-exposed person requires immediate airway support and naloxone consideration.
  • Melaena, haematemesis, intracranial symptoms or falling haemoglobin during antithrombotic treatment requires urgent bleeding and reversal assessment.
  • Collapse, bradycardia, prolonged QT, broad-complex rhythm or severe electrolyte disturbance after a medicine change needs monitored acute care.
  • New delirium, falls, urinary retention or constipation after adding an anticholinergic or sedative should trigger prompt toxicity review.
  • Vomiting, dehydration or sepsis while taking renally cleared medicines can cause rapid accumulation and requires sick-day and renal assessment.
  • Conflicting supplies, duplicate brands, missed monitored medicines or inability to self-administer safely creates an urgent medicines and support risk.

Investigations

  1. 01
    Best possible medicines historyFirst step
    Why
    Establish actual exposure before making decisions.
    Interpretation and limitations
    Compare multiple sources and resolve ingredient, dose, route, indication, last administration, adherence and allergy discrepancies.
  2. 02
    Function, cognition and capacity assessment
    Why
    Determine treatment goals and administration ability.
    Interpretation and limitations
    Assess ADLs, falls, frailty, memory, dexterity, vision, swallowing, support and decision-specific capacity rather than medicine count alone.
  3. 03
    Postural physiology and focused examination
    Why
    Connect symptoms with drug effects or disease.
    Interpretation and limitations
    Record symptoms with lying-standing pressure, pulse, hydration, gait, cognition and relevant organ findings before attributing causality.
  4. 04
    Renal, electrolyte and liver profile
    Why
    Identify altered clearance and treatment harm.
    Interpretation and limitations
    Use trends and medicine-specific renal calculation; a creatinine within range can conceal major clearance loss in low muscle mass.
  5. 05
    Targeted safety monitoring
    Why
    Check high-risk therapy against its indication.
    Interpretation and limitations
    Select FBC, INR, glucose records, drug level, ECG or other tests from the medicines and symptoms, avoiding indiscriminate panels.
  6. 06
    Pharmacy supply and administration review
    Why
    Find duplicate supply and practical failure.
    Interpretation and limitations
    Inspect packs, dispensing intervals, technique, ordering, storage and who administers each dose in the real setting.

Differential diagnosis

01

Acute illness

Infection, stroke, metabolic disturbance and dehydration can mimic medicine toxicity and also precipitate it by changing physiology.

02

Disease progression

Heart failure, Parkinsonism, dementia or pain may genuinely worsen; chronology and dechallenge evidence prevent automatic drug attribution.

03

Non-adherence or access failure

Missed supply, affordability, swallowing, beliefs and carer limitations can produce apparent treatment resistance or withdrawal symptoms.

04

Administration error

Duplicate packs, incorrect inhaler technique, unsuitable formulation or wrong timing can cause harm despite an accurate prescription list.

Management

01First-line structured reviewReconcile, prioritise and agreeFirst stepFirst linePolypharmacy, frailty or a transition creates potential medicine-related harm.+
  1. 1Establish the person's priorities, stable baseline, prognosis, functional goals and actual medicine exposure from reliable sources.
  2. 2Review each item for indication, benefit, safety, monitoring, interaction, adherence, formulation and time to benefit.
  3. 3Agree a ranked plan with implementation, withdrawal and relapse safeguards, named owners and a specific review date.
02Acute harm routeTreat toxicity before optimisationPhysiological instability, bleeding, hypoglycaemia, respiratory depression or severe delirium is present.+
  1. 1Stabilise with ABCDE, glucose, ECG and targeted tests while withholding further suspected exposure.
  2. 2Identify exact drugs, dose, last administration, renal function and interacting agents and seek antidote or poisons advice.
  3. 3After recovery, correct the regimen and administration system and communicate the causal analysis across care settings.
03Complex multimorbidity routeAlign medicines with lived prioritiesGuidelines compete or treatment burden exceeds capacity.+
  1. 1Identify conditions and outcomes the person prioritises and which recommendations offer realistic benefit within their context.
  2. 2Coordinate prescribers to reduce duplication, simplify timing and preserve treatments with current symptomatic or prognostic value.
  3. 3Use shared decisions or supported best-interests decisions and monitor function, symptoms and disease control after change.
04Transition follow-throughMake one plan survive handoverHospital, care-home or specialist transition changes the list.+
  1. 1Reconcile against the pre-transition regimen and distinguish intentional change from omission or duplication.
  2. 2Send the indication, decision, monitoring, pending results and stop or restart criteria to GP, pharmacy and care team.
  3. 3Confirm supply and understanding soon after transition and repeat review when physiology or support changes.

Complications

01

Falls and functional loss

Sedation, postural hypotension, hypoglycaemia and impaired coordination cause injury, fear, deconditioning and new dependency after a previously manageable routine.

02

Delirium and cognitive harm

Anticholinergic load, opioids, psychoactive treatment and acute accumulation can precipitate fluctuating attention, unsafe behaviour and prolonged loss of independence.

03

Bleeding and organ injury

Antithrombotic combinations, nephrotoxic exposure and electrolyte disturbance can cause gastrointestinal, intracranial, renal or cardiac emergencies requiring hospital treatment.

04

Non-adherence and inequity

An unmanageable regimen leads to selective omission, wasted medicines and unequal outcomes for people dependent on carers or communication support.

05

Hospital and care transition

Medication-related admission can trigger delirium, mobility loss and placement change unless the causal regimen and support system are corrected.

Monitoring and follow-up

  • Review new symptoms, falls, cognition, blood pressure and function after each material medicine change.
  • Complete medicine-specific renal, electrolyte, blood count, ECG, glucose or concentration monitoring at the agreed interval.
  • Check that discontinued items were removed from repeats, monitored packs, care records and automatic ordering systems.
  • Track the intended clinical benefit of retained medicines rather than assuming prescription equals effectiveness.
  • Reassess adherence, swallowing, technique, supply and carer capacity after every transition or functional decline.
  • Repeat structured review after admission, new frailty, organ deterioration, recurrent falls or a major change in goals.

Special situations

Count is not the diagnosis

Ten justified, monitored medicines may be safer than three with no indication or reliable administration.

Creatinine can reassure falsely

Low muscle mass may keep serum creatinine modest while drug clearance has fallen substantially.

A blister pack is not reconciliation

Packaging organises whatever was prescribed; it cannot correct duplication, dose error or poor indication.

Stopping requires ownership

The clinician changing treatment remains responsible for withdrawal, recurrence and communication planning.

Function is a safety outcome

Fewer falls, clearer cognition and easier self-administration can matter more than reducing a numerical count.

Common pitfalls

  1. 01

    Deleting medicines solely to reach an arbitrary count.

  2. 02

    Reviewing the electronic repeat list without establishing actual use.

  3. 03

    Using eGFR for a drug whose product information requires Cockcroft–Gault creatinine clearance.

  4. 04

    Stopping withdrawal-prone medicines abruptly during a general tidy-up.

  5. 05

    Assuming a relative can consent without decision-specific capacity and authority review.

  6. 06

    Changing several symptom-active medicines without a way to identify relapse or withdrawal.

  7. 07

    Sending an updated list without reasons, monitoring and named ownership.